| Literature DB >> 21187817 |
Hoda Z Shams1, Rafat M Mohareb, Maher H Helal, Amira E Mahmoud.
Abstract
The reaction ofEntities:
Mesh:
Substances:
Year: 2010 PMID: 21187817 PMCID: PMC6259152 DOI: 10.3390/molecules16010052
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of the precursor 2 and its cyclized product 3.
Scheme 2Synthesis of the coumarin derivative 4 and benzal derivatives 5 and 6.
Scheme 3Synthesis of pyrazole systems 7a,b.
Scheme 4Synthesis of pyridone derivatives 9a,b.
Scheme 5Synthesis of 2-pyridone derivatives 10a-d.
Scheme 6Synthesis of the highly functionalized thiophenes 11a,b and thiazole 12.
Scheme 7Synthesis of 2-pyrimidone-6-thione 13.
Scheme 8Synthesis of thiophene derivatives 14a,b and the thiazole 15.
Scheme 9Synthesis of 2-pyridone-3-phenylazo derivatives 17a,b.
Antiproliferative activity GI50 (µM) of the synthesized compounds.
| Compound | GI50 (µM) a | ||
|---|---|---|---|
| MCF-7 | NCI-H460 | SF-268 | |
| 30.0 ± 0.6 | 19.3 ± 1.4 | 26.3 ± 1.5 | |
| 44.6 ± 12.6 | 32.6 ± 8.6 | 60.4 ± 14.8 | |
| 10.8 ± 0.6 | 16.5 ± 0.8 | 16.7 ± 1.6 | |
| 75.7 ± 17.5 | 40.2 ± 12.8 | 52.0 ± 9.0 | |
| 37.4 ± 10.2 | 22.1 ± 0.8 | 14.9 ± 6.8 | |
| 2.5 ± 0.5 | 10.4 ± 0.6 | 8.0 ± 0.4 | |
| 74.9 ± 0.9 | 40.6 ± 1.8 | 58.8 ± 0.8 | |
| 38.0 ± 1.8 | 40.0 ± 0.8 | 22.5 ± 1.1 | |
| 20.0 ± 0.2 | 30.6 ± 1.4 | 38.4 ± 0.6 | |
| 16.7 ± 1.6 | 10.8 ± 0.6 | 16.5 ± 0.8 | |
| 50.1 ± 0.7 | 23.2 ± 4.8 | 18.4 ± 1.8 | |
| 39.0 ± 1.8 | 46.0 ± 0.8 | 22.5 ± 1.1 | |
| 22.0 ± 0.2 | 30.6 ± 1.4 | 38.4 ± 0.6 | |
| 66.6 ± 12.2 | 12.0 ± 6.2 | 24.8 ± 3.2 | |
| 22.0 ± 0.4 | 26.3 ± 0.8 | 39.0 ± 0.8 | |
| 10.9 ± 0.2 | 146.1 ± 0.6 | 22.3 ± 0.5 | |
| 42.6 ± 12.2 | 32.6 ± 8.6 | 64.4 ± 14.8 | |
| 20.0 ± 0.2 | 32.6 ± 1.4 | 36.4 ± 0.6 | |
| 11.8 ± 0.6 | 14.5 ± 0.8 | 16.7 ± 1.6 | |
| 36.4 ± 10.2 | 20.1 ± 0.8 | 18.9 ± 6.8 | |
| 2.0 ± 0.4 | 8.3 ± 0.8 | 4.0 ± 0.8 | |
| 68.6 ± 12.2 | 12.0 ± 6.2 | 24.8 ± 3.2 | |
| *Doxorubicin | 0.0428 ± 0.0082 | 0.0940 ± 0.0087 | 0.0940 ± 0.0070 |
a Drug concentration required to inhibit tumor cell proliferation by 50% after continuous exposure of 48 h; data are expressed as means ±SEM of three independent experiments performed in duplicates; *Doxorubicin was used as positive control.